Federal Register / Vol. 53, No. 223 / Friday, November 18. 1988 / Notices 
46665 
Place of Meeting: Building 31C, 
Conference Room 6. 
Open: December 5. 8:30 a.m. to recess. 
December 8, 8.30 ajn. to adjournment. 
Agenda: Reports on activities of the 
President's Cancer Panel: the Acting 
Director's Remarks on the National 
Cancer Institute: Program Review of the 
NCI Divisions: Subcommittee Reports: 
and New Business. 
Dated: November 15. 1988. 
Betty J. Beveridge, 
Committee Management Officer. SIH. 
[FR Doc. 88-2S764 Filed 11-17-33. 8:45 am] 
BHJJMO COCC 4V40-01-M 
National Heart, Lung and Blood 
Institute; Meeting of the 
Arteriosclerosis, Hypertension and 
Lipid Metabolism Advisory Committee 
Pursuant to Pub. L 92-483, notice is 
hereby given of the meeting of the 
Arteriosclerosis. Hypertension and Lipid 
Metabolism Advisory Committee, 
National Heart. Lung and Blood 
Lnstitute. January 30-31. 1989. Building 
31. Conference Room 9. C-Wing. 
National Institutes of Health. Bethesda. 
Maryland 2C892. 
The entire meeting will be open to the 
public from approximately 8:30 a.m. to 
5.-00 p.m. on Monday. January 30. and 
from 8:30 a.m. to adjournment on 
Tuesday. January 31. to evaluate 
program support in arteriosclerosis, 
hypertension and lipid metabolism. 
Attendance by the public will be limited 
on a space available basis. 
Ms. Terry Bellicha. Chief. 
Communications and Public Information 
Branch. National Heart. Lung and Blood 
Institute. Building 31. Room 4A21. 
National Institutes of Health. Bethesda. 
Maryland 20892. (301) 496-1235. will 
provide a summary of the meeting and a 
roster of the committee members. 
Dr. G.C McMillan. Associate Director. 
Arteriosclerosis. Hypertension and Lipid 
Metabolism Program. NHLBI. Room 
402 . Federal Building, national 
Institutes of Health. Bethesda. MD 
20892. (301) 496-1613. will furnish 
substantive program information. 
(Catalog of Federal Domestic Assistance 
Program No. 13.837. Heart and Vascular 
Diseases Research. National Institutes of 
Health) 
Dated: November 9. 1988. 
Betty ). Beveridge, 
Committee Management Officer SIH. 
(FR Dec. 88-28670 Filed 11-17-88; 8:45 am) 
BIUJMG coot 414O-0t-M 
National Institute of Diabetes and 
Digestive and Kidney Diseases; 
Meeting, National Diabetes Advisory 
Board 
Pursuant to Pub. L 92-463. notice is 
hereby given of the National Diabetes 
Advisory Board's meeting date which 
will be December 12. 1988. The meeting 
will begin at 8:30 a.m. and end at 
approximately 4:20 p.m. The Board will 
meet at the Crystal City Marriott 1999 
Jefferson Davis Highway. Arlington. 
Virginia 22032. The purpose of the 
meeting is to discuss the Board's 
activities and to continue evaluation of 
the implementation of the long-renge 
plan to combat diabetes mellitus. 
Although the entire meeting will be open 
to the public, attendance will be limited 
to space available. Notice of the meeting 
room will be posted in the hotel lobby. 
For any further information, please 
contact Mr. Raymond M. Kuehne, 
Executive Director. National Diabetes 
Advisory Board. 1801 Rockville Pike. 
Suite 500. Rockville. Maryland 20852. 
(301) 4S6-G045. His office will provide, 
for example, a membership roster of the 
Board and an agenda and summaries of 
the actual meetings. 
Dated: November 9. 1C88. 
Betty J. Beveridge. 
SIH Committee Management Officer 
[FR Doc. 88-26671 Filed 11-17-88: 8.45 ami 
bujjmg cooe < 1 4o-oi -a 
Recombinant DNA Advisory 
Committee; Definitions Subcommittee; 
Meeting 
Pursuant to Pub. L 92-463. notice is 
hereby given of a meeting of the 
Recombinant DNA Advisory 
Committee — Definitions Subcommittee 
at the National Institutes of Health. 
Building 31. Room 2A5 2. Bethesda. 
Maryland 20892. on December 5, 1988. 
from approximately 9:00 a.m. to 
adjournment at approximately 12.-00 
noon to discuss the definition of 
"recombinant DNA" under the NIH 
Guidelines for Research Involving 
Recombinant DNA Molecules. This 
meeting will be open to the public. 
Attendance by the public will be limited 
to space available. 
Further information may be obtained 
from Mr. Robert J. Crawford. Executive 
Secretary. Office of Recombinant DNA 
Activities, National Institutes of Health. 
Building 31, Room B1C34. Bethesda. 
Maryland 20892. telephone (301) 496- 
9838. 
OMB's “Mandatory Information 
Requirement* for Federal Assistance Program 
Announcements" (45 FR 39592) requires a 
statement concerning the official 
governments programs contained in the 
Catalog of Federal Domestic Assistance. 
Normally NIH lists in its announcements the 
number and title of affected individual 
programs for the guidance of the public. 
Because the guidance in this notice covers 
not only virtually every NIH program but also 
essentially every Federal research program in 
which DNA recombinant molecule techniques 
could be used, it has been determined to be 
not cost effective or in the public interest to 
attempt to list these programs. Such a list 
would likely require several additional pagrs. 
In addition. NIH could not be certain that 
every Federal program would be included as 
many Federal agencies, as well as private 
organizations, both national ond 
international, have elected to follow the NIH 
Guidelines. In lieu of the individual program 
listing. NIH invites readers to direct 
questions to the information address above 
about whether individual programs listed in 
the Catalog of Federal Domestic Assistance 
are affected. 
Dated: November 10. 1988. 
Betty J. Beveridge, 
Committee Management Officer SIH. 
(FR Doc 88-28672 Filed 11-17-88. 8:45 am] 
BIUJMG COOC 4140-01-M 
Public Health Service 
Delegation of Authority to the 
Administrator, Health Resources and 
Services Administration 
Notice is hereby given thatrtn 
furtherance of the delegation of 
authority to the Assistant Secretary for 
Health on January 14. 198V (46 FR 10016) 
by the Secretary of Health and Human 
Services, the Assistant Secretary for 
Health has delegated all of the 
authorities under section 315 of the 
Public Health Service Act, as amended, 
pertaining to the Grants for Treatment 
Drugs for Acquired Immune Deficiency 
Syndrome, to thef Administrator. Health 
Resources and Services Administration, 
with authority to redelegate. 
Redelega'Jon: These authorities may 
be redelegated. 
Effective Date: This delegation 
became effective on November 8, 1988. 
Date: November 8. 1988. 
Robert E. Windora, 
Assistant Secretary for Health. 
FR Doc 88-28678 Filed 11-17-88; 8:45 amj 
BIUJMG COOC 
Recombinant DNA Research, Volume 13 
[279] 
